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Introduction
Mevalonate kinase deficiency (MKD) is a rare hereditary
autoinflammatory syndrome, characterized by recurrent
fever episodes with gastrointestinal complaints, rash and
arthralgia. The deficient mevalonate kinase activity leads
to elevated mevalonic acid, which is excreted in the
urine. Therefore, an elevated mevalonic acid excretion is
suggestive of MKD. However, the diagnostic value of
this analysis has not been investigated yet and remains
unclear.
Objectives
To investigate the diagnostic value of urinary mevalonic
acid excretion in patients with suspected MKD.
Methods
In this single center study, we retrospectively analyzed
the results of all patients in whom both measurement of
urinary mevalonic acid excretion and genetic analysis of
the MVK-gene had been performed in the preceding 17
years. Mevalonic acid excretion was analyzed by using
gas chromatography - mass spectrometry (GC-MS) and
was expressed as mmol/mol creatinine and compared
with age dependent reference values. The presence of
two MVK mutations was considered as gold standard
for the diagnosis of MKD.
Results
The study included 63 patients (33 male, 30 female, aged:
0-36 year) with clinical features suggestive of MKD.
Twenty-one patients had more than one assessment of
mevalonic acid excretion.
Thirteen patients harboured two MVK mutations.
These 13 MKD patients suffered predominantly from
recurrent fever episodes (n=13), diarrhoea (n=13),
abdominal pain (n=13), arthralgia (n=12), myalgia
(n=10), stomatitis (n=10) and rash (n=9). Further, arthritis
(n=6), seizures (n=3), mild mental retardation (n=2),
dysarthria (n=1) and retinitis pigmentosa (n=1) were
reported. The disease started within the first year of life in
all MKD patients. Two out of 13 had at least one negative
mevalonic acid excretion. In one patient, this measure-
ment was performed during a febrile episode. Another
patient had one normal mevalonic acid excretion along-
side five elevated assessments.
Six patients had an elevated mevalonic acid excretion,
but harboured no MVK mutations. At least two of these
assessments were performed during a fever episode.
Multiple urine analyses were performed; all of the six
patients had discrepancies between the urine analyses.
Urinary mevalonic excretion was elevated twice in two
patients, while four patients had only one elevated assess-
ment. Main symptoms were recurrent fever episodes
(n=5), abdominal pain (n=2), neutropenia (n=1), hypotonia
(n=1), dysmorphic features (n=1), mild mental retardation
and mild ataxia (n=1). None of the remaining 44 patients
with a normal mevalonic acid excretion had an MVK
mutation.
This resulted in a sensitivity of 92%, a specificity of
88%, a positive predictive value of 67% and a negative
predictive value of 98%.
Conclusion
MKD seems very unlikely in patients with a normal
mevalonic acid excretion, but it cannot be excluded
completely. Therefore, detection of urinary mevalonic
acid should not be mandatory before genetic testing.
Nonetheless, a positive urinary mevalonic acid excretion
requires MVK analysis to confirm the diagnosis MKD.
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